In collaboration with Johnson & Johnson, we are driving this Phase I clinical trial on the long-acting injectable bedaquiline forward. This trial underlines RespiriTB's commitment to advancing innovative tuberculosis (TB) treatments, potentially even transforming TB prevention and care. At our department innovative antimicrobial solutions have long been a major focus point in our research. We are happy to be part of the team around RespiriTB and to driving the progress of this project with our expertise and fully committed employees. #ClinicalResearch #ClinicalPharmacology #ClinicalExperts #Anitmicrobial #Research #MedicalResearch #PhaseIClinicalTrial
📢 Milestone Alert! 📢 We at RespiriTB are excited to report that our Phase 1 clinical trial of the long-acting injectable bedaquiline has commenced! This innovative treatment could transform TB prevention and care, addressing unmet needs in a single healthcare visit. We’re committed to delivering solutions that make a lasting impact! #RespiriTB #ClinicalTrial #PublicHealth Link to the full announcement in comments. Innovative Health Initiative (IHI) AMR Accelerator UNITE4TB ERA4TB Leiden University Medical Center Clinical Pharmacology MedUni Vienna